aMoon

aMoon is a leading Israeli life sciences venture fund. Our team is passionate about building successful businesses and helping Israeli biopharma, digital health and medical technology companies realize their potential.

Author: gilrabbi

Ushering in a New Era: The $100 Genome is Here

Posted on June 1, 2022June 1, 2022Author gilrabbiCategories Insight

Welcome to ’tissue therapeutics’: Dave Lennon’s $110M new venture will implant ‘happy cells’ that ‘survive and thrive’

 

Posted on April 20, 2022May 3, 2022Author gilrabbiCategories News

Eleos Health raises $20 million to generate insights from mental health clinician-patient conversations

Posted on April 5, 2022April 6, 2022Author gilrabbiCategories News

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy

Posted on March 7, 2022April 6, 2022Author gilrabbiCategories News

Warburg Pincus Co-Leads Latest Funding Round in Israel’s MDClone

Posted on March 1, 2022March 2, 2022Author gilrabbiCategories News

Precision immunology player bags $110M to fund its work on ‘disease signature’ tests

Posted on February 24, 2022March 2, 2022Author gilrabbiCategories News

Omada Health Valued at $1 Billion-Plus in Fidelity-Led Round

Posted on February 23, 2022March 14, 2022Author gilrabbiCategories News

Investors expect to pour more funds into digital health, survey shows

Posted on January 30, 2022March 14, 2022Author gilrabbiCategories News

12 על 12: הדמויות המשפיעות בענף ההלת’טק

Posted on January 22, 2022March 14, 2022Author gilrabbiCategories News

When the Stars Align: The Story of our Investment in Sophia Genetics

Posted on December 23, 2021January 6, 2022Author gilrabbiCategories Insight

Posts pagination

Page 1 Page 2 … Page 10 Next page
Contact Careers terms of service privacy policy
aMoon on linkedin aMoon on linkedin aMoon on twitter aMoon on twitter aMoon on youtube aMoon on youtube
Ra'anana, Israel
© aMoon Website by nym. Developed by Rabbi Interactive